Clinical trials: Emergency Contraception
Contraception
Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception
The purpose of this study is to assess the safety and efficacy of CDB-2914 in comparison to levonorgestrel for preventing pregnancy up to 5 days after unprotected sexual intercourse.
- Trial name
- NCT00551616
- Testing
- CDB-2914, Levonorgestrel
- Where
- 33 sites in United States, Ireland and 1 more
- Volunteers
- 2,221 people
- Sponsor
- HRA Pharma
Contraception, Postcoital
Effect of Piroxicam on Ovulation
In this study the effect of piroxicam on the ovulation will be evaluated. Therefore piroxicam will be administered as a single-dose after onset of LH surge (luteinizing hormone, hormone which triggers ovulation).
- Trial name
- NCT01320709
- Testing
- Piroxicam ( BAYl1902)
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception
Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women
The purpose of this observational study is to assess the safety and tolerability of ellaOne® in routine conditions of use for emergency contraception in postmenarcheal adolescents and adult women who want to prevent pregnancy up…
- Trial name
- NCT01107106
- Testing
- ellaOne® (ulipristal acetate)
- Where
- 6 sites in United States, Sweden and 1 more
- Volunteers
- 579 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Emergency Contraception
Emergency Contraception Actual Use Study
This is a non-comparative case series study to assess the ability of females 11-16 years of age, inclusive, who are requesting emergency contraception (EC) to use the study product, DR-104 (Plan B® 1.5), appropriately and safely…
- Trial name
- NCT00777556
- Testing
- DR-104
- Where
- 5 sites in United States
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Emergency Contraception
Safety and Efficacy of CDB-2914 for Emergency Contraception
The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.
- Trial name
- NCT00411684
- Testing
- CDB-2914
- Where
- 17 sites in United States
- Volunteers
- 1,623 people
- Sponsor
- HRA Pharma
Emergency Contraception
A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.
- Trial name
- LIBRella (NCT03208985)
- Testing
- Use Phase (Ulipristal Acetate, 30 mg)
- Where
- 34 sites in United States
- Volunteers
- 1,270 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Emergency Contraception
Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.
- Trial name
- ellipseII (NCT01569737)
- Testing
- ella
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Emergency Contraception
Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.
The purposes of this study are to compare the effects on ovarian activity of quick starting a Combined Oral Contraceptive Pill (COCP) after ellaOne® or placebo intake.
- Trial name
- NCT01569113
- Testing
- Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)
- Where
- 3 sites in Netherlands, Sweden and 1 more
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HRA Pharma